{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:07:08Z","timestamp":1769839628901,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,1,9]],"date-time":"2015-01-09T00:00:00Z","timestamp":1420761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s11547-014-0492-y","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T08:28:21Z","timestamp":1420705701000},"page":"557-562","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS)"],"prefix":"10.1007","volume":"120","author":[{"given":"Tomohiro","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Tamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotake","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Kanki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasufumi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Higaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,9]]},"reference":[{"key":"492_CR1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","volume":"356","author":"SE Cowper","year":"2000","unstructured":"Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000\u20131001","journal-title":"Lancet"},{"key":"492_CR2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00000372-200110000-00001","volume":"23","author":"SE Cowper","year":"2001","unstructured":"Cowper SE, Su LD, Bhawan J et al (2001) Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23:383\u2013393","journal-title":"Am J Dermatopathol"},{"key":"492_CR3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00002281-200311000-00017","volume":"15","author":"SE Cowper","year":"2003","unstructured":"Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6\u00a0years. Curr Opin Rheumatol 15:785\u2013790","journal-title":"Curr Opin Rheumatol"},{"key":"492_CR4","first-page":"1654","volume":"14","author":"HS Thomsen","year":"2004","unstructured":"Thomsen HS (2004) Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 14:1654\u20131656","journal-title":"Eur Radiol"},{"key":"492_CR5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/ndt\/gfh473","volume":"20","author":"T Schmook","year":"2005","unstructured":"Schmook T, Budde K, Ulrich C et al (2005) Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrol Dial Transplant 20:220\u2013222","journal-title":"Nephrol Dial Transplant"},{"key":"492_CR6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1525-139X.2006.00152.x","volume":"19","author":"DM DeHoratius","year":"2006","unstructured":"DeHoratius DM, Cowper SE (2006) Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 19:191\u2013194","journal-title":"Semin Dial"},{"key":"492_CR7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2215\/CJN.00030107","volume":"2","author":"MA Perazella","year":"2007","unstructured":"Perazella MA (2007) Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2:200\u2013202","journal-title":"Clin J Am Soc Nephrol"},{"key":"492_CR8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1525-139X.2007.00269.x","volume":"20","author":"MA Perazella","year":"2007","unstructured":"Perazella MA, Rodby RA (2007) Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 20:179\u2013185","journal-title":"Semin Dial"},{"key":"492_CR9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1148\/radiol.2431062144","volume":"243","author":"EA Sadowski","year":"2007","unstructured":"Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148\u2013157","journal-title":"Radiology"},{"key":"492_CR10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MOU.0b013e328011c96f","volume":"17","author":"HS Thomsen","year":"2007","unstructured":"Thomsen HS (2007) European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 17:70\u201376","journal-title":"Curr Opin Urol"},{"key":"492_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1148\/radiol.2461071267","volume":"246","author":"E Kanal","year":"2008","unstructured":"Kanal E, Broome DR, Martin DR et al (2008) Response to the FDA\u2019s May 23, 2007, nephrogenic systemic fibrosis update. Radiology 246:11\u201314","journal-title":"Radiology"},{"key":"492_CR12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1148\/radiol.2483071863","volume":"248","author":"MR Prince","year":"2008","unstructured":"Prince MR, Zhang H, Morris M et al (2008) Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248:807\u2013816","journal-title":"Radiology"},{"key":"492_CR13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1148\/radiol.2483072093","volume":"248","author":"R Wertman","year":"2008","unstructured":"Wertman R, Altun E, Martin DR et al (2008) Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248:799\u2013806","journal-title":"Radiology"},{"key":"492_CR14","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1148\/radiol.2533090649","volume":"253","author":"E Altun","year":"2009","unstructured":"Altun E, Martin DR, Wertman R et al (2009) Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy\u2014report from two US universities. Radiology 253:689\u2013696","journal-title":"Radiology"},{"key":"492_CR15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/RLI.0b013e3181998eb7","volume":"44","author":"H Pietsch","year":"2009","unstructured":"Pietsch H, Lengsfeld P, Steger-Hartmann T et al (2009) Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 44:226\u2013233","journal-title":"Invest Radiol"},{"key":"492_CR16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000128407","volume":"16","author":"E Proctor","year":"1984","unstructured":"Proctor E, Chatamra K (1984) Standardized micronodular cirrhosis in the rat. Eur Surg Res 16:182\u2013186","journal-title":"Eur Surg Res"},{"key":"492_CR17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/01.rli.0000209657.16115.42","volume":"41","author":"MV Knopp","year":"2006","unstructured":"Knopp MV, Balzer T, Esser M et al (2006) Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15\u00a0years of clinical use. Invest Radiol 41:491\u2013499","journal-title":"Invest Radiol"},{"key":"492_CR18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.rli.0000251565.61487.1a","volume":"42","author":"P Bourrinet","year":"2007","unstructured":"Bourrinet P, Martel E, El Amrani AI et al (2007) Cardiovascular safety of gadoterate meglumine (Gd-DOTA). Invest Radiol 42:63\u201377","journal-title":"Invest Radiol"},{"key":"492_CR19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/01.rli.0000248893.01067.e5","volume":"42","author":"CU Herborn","year":"2007","unstructured":"Herborn CU, Honold E, Wolf M et al (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 42:58\u201362","journal-title":"Invest Radiol"},{"key":"492_CR20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002142-200108000-00007","volume":"12","author":"VM Runge","year":"2001","unstructured":"Runge VM (2001) Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12:309\u2013314","journal-title":"Top Magn Reson Imaging"},{"key":"492_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/RLI.0b013e31815e6277","volume":"43","author":"MA Sieber","year":"2008","unstructured":"Sieber MA, Pietsch H, Walter J et al (2008) A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 43:65\u201375","journal-title":"Invest Radiol"},{"key":"492_CR22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1525-139X.2007.00408.x","volume":"21","author":"JG Penfield","year":"2008","unstructured":"Penfield JG, Reilly RF (2008) Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 21:129\u2013134","journal-title":"Semin Dial"},{"key":"492_CR23","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jmri.21985","volume":"30","author":"T Leiner","year":"2009","unstructured":"Leiner T, Kucharczyk W (2009) Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 30:1233\u20131235","journal-title":"J Magn Reson Imaging"},{"key":"492_CR24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.rcl.2009.05.003","volume":"47","author":"HS Thomsen","year":"2009","unstructured":"Thomsen HS (2009) Nephrogenic systemic fibrosis: history and epidemiology. Radiol Clin North Am 47:827\u2013831","journal-title":"Radiol Clin North Am"},{"key":"492_CR25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/RLI.0b013e31821a218a","volume":"46","author":"S Gschwend","year":"2011","unstructured":"Gschwend S, Ebert W, Schultze-Mosgau M et al (2011) Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol 46:556\u2013566","journal-title":"Invest Radiol"},{"key":"492_CR26","first-page":"927","volume":"43","author":"G Schuhmann-Giampieri","year":"1993","unstructured":"Schuhmann-Giampieri G, Frenzel T, Schmitt-Willich H (1993) Pharmacokinetics in rats, dogs and monkeys of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. Arzneimittelforschung 43:927\u2013931","journal-title":"Arzneimittelforschung"},{"key":"492_CR27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1148\/radiology.195.3.7754011","volume":"195","author":"B Hamm","year":"1995","unstructured":"Hamm B, Staks T, Muhler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785\u2013792","journal-title":"Radiology"},{"key":"492_CR28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00004424-199402000-00017","volume":"29","author":"A Muhler","year":"1994","unstructured":"Muhler A, Heinzelmann I, Weinmann HJ (1994) Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats. Invest Radiol 29:213\u2013216","journal-title":"Invest Radiol"},{"key":"492_CR29","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.mri.2013.03.025","volume":"31","author":"T Sato","year":"2013","unstructured":"Sato T, Ito K, Tamada T et al (2013) Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Magn Reson Imaging 31:1412\u20131417","journal-title":"Magn Reson Imaging"},{"key":"492_CR30","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1021\/cr980440x","volume":"99","author":"P Caravan","year":"1999","unstructured":"Caravan P, Ellison JJ, McMurry TJ et al (1999) Gadolinium (III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99:2293\u20132352","journal-title":"Chem Rev"},{"key":"492_CR31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1259\/bjr\/17111243","volume":"80","author":"SK Morcos","year":"2007","unstructured":"Morcos SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Brit J Radiol 80:73\u201376","journal-title":"Brit J Radiol"},{"key":"492_CR32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00330-010-1951-z","volume":"21","author":"SK Morcos","year":"2011","unstructured":"Morcos SK (2011) Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? Eur Radiology 21:496\u2013500","journal-title":"Eur Radiology"},{"key":"492_CR33","doi-asserted-by":"crossref","unstructured":"Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H et al (1991) A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 22:233-237; discussion 242","DOI":"10.1002\/mrm.1910220214"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-014-0492-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11547-014-0492-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-014-0492-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T16:33:06Z","timestamp":1559406786000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11547-014-0492-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,9]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1007\/s11547-014-0492-y","relation":{},"ISSN":["0033-8362","1826-6983"],"issn-type":[{"value":"0033-8362","type":"print"},{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,9]]}}}